- Home
- TCBP vs ENVB Comparison
TCBP vs ENVB Comparison
Compare TCBP & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBP
- ENVB
- Stock Information
- Founded
- TCBP 2013
- ENVB 1994
- Country
- TCBP United Kingdom
- ENVB United States
- Employees
- TCBP N/A
- ENVB N/A
- Industry
- TCBP Biotechnology: Biological Products (No Diagnostic Substances)
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- TCBP Health Care
- ENVB Health Care
- Exchange
- TCBP Nasdaq
- ENVB Nasdaq
- Market Cap
- TCBP 831.0K
- ENVB 3.5M
- IPO Year
- TCBP 2022
- ENVB N/A
- Fundamental
- Price
- TCBP $1.69
- ENVB $1.64
- Analyst Decision
- TCBP Strong Buy
- ENVB Strong Buy
- Analyst Count
- TCBP 1
- ENVB 1
- Target Price
- TCBP $48.00
- ENVB $10.00
- AVG Volume (30 Days)
- TCBP 632.6K
- ENVB 8.1M
- Earning Date
- TCBP 11-25-2024
- ENVB 03-25-2025
- Dividend Yield
- TCBP N/A
- ENVB N/A
- EPS Growth
- TCBP N/A
- ENVB N/A
- EPS
- TCBP N/A
- ENVB N/A
- Revenue
- TCBP N/A
- ENVB N/A
- Revenue This Year
- TCBP N/A
- ENVB N/A
- Revenue Next Year
- TCBP N/A
- ENVB N/A
- P/E Ratio
- TCBP N/A
- ENVB N/A
- Revenue Growth
- TCBP N/A
- ENVB N/A
- 52 Week Low
- TCBP $1.43
- ENVB $1.13
- 52 Week High
- TCBP $523.20
- ENVB $420.75
- Technical
- Relative Strength Index (RSI)
- TCBP 28.01
- ENVB 21.19
- Support Level
- TCBP $1.43
- ENVB $1.60
- Resistance Level
- TCBP $2.19
- ENVB $1.78
- Average True Range (ATR)
- TCBP 0.28
- ENVB 0.44
- MACD
- TCBP 0.19
- ENVB 2.18
- Stochastic Oscillator
- TCBP 20.57
- ENVB 15.13
About TCBP TC BioPharm (Holdings) plc
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.